Social Stress and Psychosis Risk: Common Neurochemical Substrates ?

Neuropsychopharmacology

Volumn 41, Issue 3, 2016, Pages 666-674

  Mizrahi, Romina ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CANNABINOID; CANNABINOID 1 RECEPTOR; DOPAMINE; ENDOCANNABINOID; HYDROCORTISONE;

BEHAVIOR; CANNABIS USE; DISEASE ASSOCIATION; DISEASE COURSE; DOPAMINERGIC SYSTEM; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INFLAMMATION; MENTAL STRESS; NERVOUS SYSTEM INFLAMMATION; NEUROCHEMISTRY; NONHUMAN; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SOCIAL ENVIRONMENT; SOCIAL STRESS; ANIMAL; BRAIN; METABOLISM; PERCEPTION; PSYCHOLOGY;

ANIMALS; BRAIN; DOPAMINE; HUMANS; PSYCHOTIC DISORDERS; SOCIAL PERCEPTION; STRESS, PSYCHOLOGICAL;

EID: 84953851637     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2015.274     Document Type: Review

References (115)

1. Abi-Dargham A, van de Giessen E, Slifstein M, Kegeles LS, Laruelle M (2009). Baseline and amphetamine-stimulated dopamine activity are related in drug-naïve schizophrenic subjects. Biol Psychiatry 65: 1091-1093.
2. Adler CM, Elman I, Weisenfeld N, Kestler L, Pickar D, Breier A (2000). Effects of acute metabolic stress on striatal dopamine release in healthy volunteers. Neuropsychopharmacology 22: 545-550.
3. Akdeniz C, Tost H, Streit F et al (2014). Neuroimaging evidence for a role of neural social stress processing in ethnic minorityassociated environmental risk. JAMA Psychiatry 71: 672-680.
4. Andreasson S, Allebeck P, Engstrom A, Rydberg U (1987). Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 2: 1483-1486.
5. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE (2002). Cannabis use in adolescence and risk for adult psychosis: Longitudinal prospective study. BMJ 325: 1212-1213.
6. Atsak P, Roozendaal B, Campolongo P (2012). Role of the endocannabinoid system in regulating glucocorticoid effects on memory for emotional experiences. Neuroscience 204: 104-116.
7. Benes FM (1999). Evidence for altered trisynaptic circuitry in schizophrenic hippocampus. Biol Psychiatry 46: 589-599.
8. Bioque M, Garcia-Bueno B, Macdowell KS, Meseguer A, Saiz PA, Parellada M et al (2013). Peripheral endocannabinoid system dysregulation in first-episode psychosis. Neuropsychopharmacology 38: 2568-2577.
9. Bloomfield MA, Morgan CJ, Egerton A, Kapur S, Curran HV, Howes OD (2014). Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol Psychiatry 75: 470-478.
10. Bottlender R, Strauss A, Moller HJ (2000). Prevalence and background factors of depression in first admitted schizophrenic patients. Acta Psychiatr Scand 101: 153-160.
11. Boydell J, van Os J, McKenzie K, Allardyce J, Goel R, McCreadie RG et al (2001). Incidence of schizophrenia in ethnic minorities in London: Ecological study into interactions with environment. BMJ 323: 1336-1338.
12. Cabungcal JH, Counotte DS, Lewis EM, Tejeda HA, Piantadosi P, Pollock C et al (2014). Juvenile antioxidant treatment prevents adult deficits in a developmental model of schizophrenia. Neuron 83: 1073-1084.
13. Campolongo P, Roozendaal B, Trezza V, Hauer D, Schelling G, McGaugh JL et al (2009). Endocannabinoids in the rat basolateral amygdala enhance memory consolidation and enable glucocorticoid modulation of memory. Proc Natl Acad Sci USA 106: 4888-4893.
14. Carpenter LL, Gawuga CE, Tyrka AR, Lee JK, Anderson GM, Price LH (2010). Association between plasma IL-6 response to acute stress and early-life adversity in healthy adults. Neuropsychopharmacology 35: 2617-2623.
15. Carrier EJ, Auchampach JA, Hillard CJ (2006). Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA 103: 7895-7900.
16. Carroll JE, Low CA, Prather AA, Cohen S, Fury JM, Ross DC et al (2011). Negative affective responses to a speech task predict changes in interleukin (IL)-6. Brain Behav Immun 25: 232-238.
17. Carter CS, Bullmore ET, Harrison P (2014). Is there a flame in the brain in psychosis? Biol Psychiatry 75: 258-259.
18. Case M, Stauffer VL, Ascher-Svanum H, Conley R, Kapur S, Kane JM et al (2011). The heterogeneity of antipsychotic response in the treatment of schizophrenia. Psychol Med 41: 1291-1300.
19. Cass DK, Flores-Barrera E, Thomases DR, Vital WF, Caballero A, Tseng KY (2014). CB1 cannabinoid receptor stimulation during adolescence impairs the maturation of GABA function in the adult rat prefrontal cortex. Mol Psychiatry 19: 536-543.
20. Ceccarini J, De Hert M, Van Winkel R, Peuskens J, Bormans G, Kranaster L et al (2013). Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia. Neuroimage 79: 304-312.
21. Coelho R, Viola TW, Walss-Bass C, Brietzke E, Grassi-Oliveira R (2014). Childhood maltreatment and inflammatory markers: A systematic review. Acta Psychiatr Scand 129: 180-192.
22. Consortium SWGotPG (2014). Biological insights from 108 schizophrenia-associated genetic loci. Nature 511: 421-427.
23. Coyle JT (2012). NMDA receptor and schizophrenia: A brief history. Schizophr Bull 38: 920-926.
24. Damont A, Roeda D, Dolle F (2013). The potential of carbon-11 and fluorine-18 chemistry: Illustration through the development of positron emission tomography radioligands targeting the translocator protein 18 kDa. J Labelled Comp Radiopharm 56: 96-104.
25. Danese A, Moffitt TE, Pariante CM, Ambler A, Poulton R, Caspi A (2008). Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Arch Gen Psychiatry 65: 409-415.
26. Danese A, Pariante CM, Caspi A, Taylor A, Poulton R (2007). Childhood maltreatment predicts adult inflammation in a lifecourse study. Proc Natl Acad Sci USA 104: 1319-1324.
27. Dennison U, McKernan D, Cryan J, Dinan T (2012). Schizophrenia patients with a history of childhood trauma have a proinflammatory phenotype. Psychol Med 42: 1865-1871.
28. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC et al (1994). Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372: 686-691.
29. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R (2007). C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res 93: 261-265.
30. Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yolken R (2012). Additive effects of elevated C-reactive protein and exposure to herpes simplex virus type 1 on cognitive impairment in individuals with schizophrenia. Schizophr Res 134: 83-88.
31. Elman I, Adler CM, Malhotra AK, Bir C, Pickar D, Breier A (1998). Effect of acute metabolic stress on pituitary-adrenal axis activation in patients with schizophrenia. Am J Psychiatry 155: 979-981.
32. Fowler IL, Carr VJ, Carter NT, Lewin TJ (1998). Patterns of current and lifetime substance use in schizophrenia. Schizophr Bull 24: 443-455.
33. Frank MG, Miguel ZD, Watkins LR, Maier SF (2010). Prior exposure to glucocorticoids sensitizes the neuroinflammatory and peripheral inflammatory responses to E. coli lipopolysaccharide. Brain Behav Immun 24: 19-30.
34. Gan JO, Bowline E, Lourenco FS, Pickel VM (2014). Adolescent social isolation enhances the plasmalemmal density of NMDA NR1 subunits in dendritic spines of principal neurons in the basolateral amygdala of adult mice. Neuroscience 258: 174-183.
35. Ginovart N, Tournier BB, Moulin-Sallanon M, Steimer T, Ibanez V, Millet P (2012). Chronic Delta(9)-tetrahydrocannabinol exposure induces a sensitization of dopamine D(2)/(3) receptors in the mesoaccumbens and nigrostriatal systems. Neuropsychopharmacology 37: 2355-2367.
36. Giovanoli S, Engler H, Engler A, Richetto J, Voget M, Willi R et al (2013). Stress in puberty unmasks latent neuropathological consequences of prenatal immune activation in mice. Science 339: 1095-1099.
37. Hafner H, Maurer K, an der Heiden W (2013). ABC Schizophrenia study: An overview of results since 1996. Soc Psychiatry Psychiatric Epidemiol 48: 1021-1031.
38. Harkany T, Mackie K, Doherty P (2008). Wiring and firing neuronal networks: Endocannabinoids take center stage. Curr Opin Neurobiol 18: 338-345.
39. Harley M, Kelleher I, Clarke M, Lynch F, Arseneault L, Connor D et al (2010). Cannabis use and childhood trauma interact additively to increase the risk of psychotic symptoms in adolescence. Psychol Med 40: 1627-1634.
40. Harvey SB, Dean K, Morgan C, Walsh E, Demjaha A, Dazzan P et al (2008). Self-harm in first-episode psychosis. Br J Psychiatry 192: 178-184.
41. Heinz A (2002). Dopaminergic dysfunction in alcoholism and schizophrenia-psychopathological and behavioral correlates. Eur Psychiatry 17: 9-16.
42. Heinz A, Saunders RC, Kolachana BS, Jones DW, Gorey JG, Bachevalier J et al (1999). Striatal dopamine receptors and transporters in monkeys with neonatal temporal limbic damage. Synapse 32: 71-79.
43. Hepgul N, Pariante CM, Dipasquale S, DiForti M, Taylor H, Marques TR et al (2012). Childhood maltreatment is associated with increased body mass index and increased C-reactive protein levels in first-episode psychosis patients. Psychol Med 42: 1893-1901.
44. Herman JP, Ostrander MM, Mueller NK, Figueiredo H (2005). Limbic system mechanisms of stress regulation: Hypothalamopituitary-adrenocortical axis. Prog Neuropsychopharmacol Biol Psychiatry 29: 1201-1213.
45. Hill MN, Kumar SA, Filipski SB, Iverson M, Stuhr KL, Keith JM et al (2013). Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure. Mol Psychiatry 18: 1125-1135.
46. Hill MN, McLaughlin RJ, Morrish AC, Viau V, Floresco SB, Hillard CJ et al (2009). Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology 34: 2733-2745.
47. Hill MN, Patel S, Carrier EJ, Rademacher DJ, Ormerod BK, Hillard CJ et al (2005). Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 30: 508-515.
48. Hirsch S, Bowen J, Emami J, Cramer P, Jolley A, Haw C et al (1996). A one year prospective study of the effect of life events and medication in the aetiology of schizophrenic relapse. Br J Psychiatry 168: 49-56.
49. Horti AG, Fan H, Kuwabara H, Hilton J, Ravert HT, Holt DP et al (2006). 11C-JHU75528: A radiotracer for PET imaging of CB1 cannabinoid receptors. J Nucl Med 47: 1689-1696.
50. Howes OD, Kapur S (2009). The dopamine hypothesis of schizophrenia: Version III-the final common pathway. Schizophr Bull 35: 549-562.
51. Howes OD, Murray RM (2014). Schizophrenia: An integrated sociodevelopmental-cognitive model. Lancet 383: 1677-1687.
52. Jaremka LM, Fagundes CP, Peng J, Bennett JM, Glaser R, Malarkey WB et al (2013). Loneliness promotes inflammation during acute stress. Psychol Sci 24: 1089-1097.
53. Javitt DC (2012). Twenty-five years of glutamate in schizophrenia: Are we there yet? Schizophr Bull 38: 911-913.
54. Jenko KJ, Hirvonen J, Henter ID, Anderson KB, Zoghbi SS, Hyde TM et al (2012). Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia. Schizophr Res 141: 185-188.
55. Jiang Z, Rompala GR, Zhang S, Cowell RM, Nakazawa K (2013). Social isolation exacerbates schizophrenia-like phenotypes via oxidative stress in cortical interneurons. Biol Psychiatry 73: 1024-1034.
56. Katona I, Freund TF (2008). Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 14: 923-930.
57. Kiecolt-Glaser JK, McGuire L, Robles TF, Glaser R (2002). Psychoneuroimmunology: Psychological influences on immune function and health. J Consult Clin Psychol 70: 537-547.
58. Koethe D, Giuffrida A, Schreiber D, Hellmich M, Schultze-Lutter F, Ruhrmann S et al (2009). Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br J Psychiatry 194: 371-372.
59. Krabbendam L, van Os J (2005). Schizophrenia and urbanicity: A major environmental influence-conditional on genetic risk. Schizophr Bull 31: 795-799.
60. Kreitzer AC, Regehr WG (2002). Retrograde signaling by endocannabinoids. Curr Opin Neurobiol 12: 324-330.
61. Laruelle M, Abi-Dargham A (1999). Dopamine as the wind of the psychotic fire: New evidence from brain imaging studies. J Psychopharmacol 13: 358-371.
62. Lederbogen F, Kirsch P, Haddad L, Streit F, Tost H, Schuch P et al (2011). City living and urban upbringing affect neural social stress processing in humans. Nature 474: 498-501.
63. Leweke FM, Giuffrida A, Koethe D, Schreiber D, Nolden BM, Kranaster L et al (2007). Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: Impact of cannabis use. Schizophr Res 94: 29-36.
64. Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C et al (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2: E94.
65. Littleton JM, Maclean KI, Brownlee G (1976). Proceedings: Alterations in dopamine uptake in rat corpus striatum induced by combinations of stress and delta8-tetrahydrocannabinol (delta8-THC). Br J Pharmacol 56: 370P.
66. Lodge DJ, Grace AA (2007). Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. J Neurosci 27: 11424-11430.
67. Long LE, Lind J, Webster M, Weickert CS (2012). Developmental trajectory of the endocannabinoid system in human dorsolateral prefrontal cortex. BMC Neurosci 13: 87.
68. MacLean KI, Littleton JM (1977). Environmental stress as a factor in the response of rat brain catecholamine metabolism to delta8-tetrahydrocannabinol. Eur J Pharmacol 41: 171-182.
69. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG et al (2002). The endogenous cannabinoid system controls extinction of aversive memories. Nature 418: 530-534.
70. Miller AH, Maletic V, Raison CL (2009). Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression. Biol Psychiatry 65: 732-741.
71. Miller GE, Chen E (2010). Harsh family climate in early life presages the emergence of a proinflammatory phenotype in adolescence. Psychol Sci 21: 848-856.
72. Mizrahi R, Addington J, Rusjan PM, Suridjan I, Ng A, Boileau I et al (2012). Increased stress-induced dopamine release in psychosis. Biol Psychiatry 71: 561-567.
73. Mizrahi R, Kenk M, Suridjan I, Boileau I, George TP, McKenzie K et al (2014). Stress-induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use. Neuropsychopharmacology 39: 1479-1489.
74. Mondelli V, Cattaneo A, Belvederi Murri M, Di Forti M, Handley R, Hepgul N et al (2011). Stress and inflammation reduce brainderived neurotrophic factor expression in first-episode psychosis: A pathway to smaller hippocampal volume. J Clin Psychiatry 72: 1677-1684.
75. Mondelli V, Dazzan P, Hepgul N, Di Forti M, Aas M, D'Albenzio A et al (2010). Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: The role of stress and of antipsychotic treatment. Schizophr Res 116: 234-242.
76. Montgomery AJ, Mehta MA, Grasby PM (2006). Is psychological stress in man associated with increased striatal dopamine levels?: A [11C]raclopride PET study. Synapse 60: 124-131.
77. Morgan C, Fearon P (2007). Social experience and psychosis insights from studies of migrant and ethnic minority groups. Epidemiol Psichiatr Soc 16: 118-123.
78. Morgan CJ, Page E, Schaefer C, Chatten K, Manocha A, Gulati S et al (2013). Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms. Br J Psychiatry 202: 381-382.
79. Myin-Germeys I, Marcelis M, Krabbendam L, Delespaul P, van Os J (2005). Subtle fluctuations in psychotic phenomena as functional states of abnormal dopamine reactivity in individuals at risk. Biol Psychiatry 58: 105-110.
80. Nelson MD, Saykin AJ, Flashman LA, Riordan HJ (1998). Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging. Archiv Gen Psychiatry 55: 433.
81. Nuechterlein KH, Dawson ME, Gitlin M, Ventura J, Goldstein MJ, Snyder KS et al (1992). Developmental processes in schizophrenic disorders: Longitudinal studies of vulnerability and stress. Schizophr Bull 18: 387-425.
82. Pace TW, Miller AH (2009). Cytokines and glucocorticoid receptor signaling. Relevance to major depression. Ann N Y Acad Sci 1179: 86-105.
83. Pallanti S, Quercioli L, Pazzagli A (1997). Relapse in young paranoid schizophrenic patients: A prospective study of stressful life events, P300 measures, and coping. Am J Psychiatry 154: 792-798.
84. Pedersen A, Diedrich M, Kaestner F, Koelkebeck K, Ohrmann P, Ponath G et al (2008). Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 32: 1789-1792.
85. Perlman WR, Webster MJ, Kleinman JE, Weickert CS (2004). Reduced glucocorticoid and estrogen receptor alpha messenger ribonucleic acid levels in the amygdala of patients with major mental illness. Biol Psychiatry 56: 844-852.
86. Perkins DO, Jeffries CD, Addington J, Bearden CE, Cadenhead KS et al (2015). Towards a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: Preliminary results from the NAPLS project. Schizophr Bull 41: 419-428.
87. Popoli M, Yan Z, McEwen B, Sanacora G (2011). The stressed synapse: The impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci 13: 22-37.
88. Prescot AP, Renshaw PF, Yurgelun-Todd DA (2013). Gammaamino butyric acid and glutamate abnormalities in adolescent chronic marijuana smokers. Drug Alcohol Depend 129: 232-239.
89. Pruessner JC, Champagne F, Meaney MJ, Dagher A (2004). Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: A positron emission tomography study using [11C]raclopride. J Neurosci 24: 2825-2831.
90. Rademacher DJ, Meier SE, Shi L, Ho WS, Jarrahian A, Hillard CJ (2008). Effects of acute and repeated restraint stress on endocannabinoid content in the amygdala, ventral striatum, and medial prefrontal cortex in mice. Neuropharmacology 54: 108-116.
91. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL et al (1990). Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264: 2511-2518.
92. Rhen T, Cidlowski JA (2005). Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 353: 1711-1723.
93. Robinson TE, Berridge KC (1993). The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Res Rev 18: 247-291.
94. Robson PJ, Guy GW, Di Marzo V (2014). Cannabinoids and schizophrenia: Therapeutic prospects. Curr Pharmaceut Des 20: 2194-2204.
95. Selten JP, Cantor-Graae E, Kahn RS (2007). Migration and schizophrenia. Curr Opin Psychiatry 20: 111-115.
96. Selten JP, van der Ven E, Rutten BP, Cantor-Graae E (2013). The social defeat hypothesis of schizophrenia: An update. Schizophr Bull 39: 1180-1186.
97. Squires EC, McClure HH, Martinez CR Jr, Eddy JM, Jimenez RA, Isiordia LE et al (2012). Diurnal cortisol rhythms among Latino immigrants in Oregon, USA. J Physiol Anthropol 31: 19.
98. Stafford MR, Jackson H, Mayo-Wilson E, Morrison AP, Kendall T (2013). Early interventions to prevent psychosis: Systematic review and meta-analysis. BMJ 346: F185.
99. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D et al (2009). Common variants conferring risk of schizophrenia. Nature 460: 744-747.
100. Suplita RL 2nd, Eisenstein SA, Neely MH, Moise AM, Hohmann AG (2008). Cross-sensitization and cross-tolerance between exogenous cannabinoid antinociception and endocannabinoidmediated stress-induced analgesia. Neuropharmacology 54: 161-171.
101. Thompson JL, Urban N, Slifstein M, Xu X, Kegeles LS, Girgis RR et al (2013). Striatal dopamine release in schizophrenia comorbid with substance dependence. Mol Psychiatry 18: 909-915.
102. Tull ES, Sheu Y-T, Butler C, Cornelious K (2005). Relationships between perceived stress, coping behavior and cortisol secretion in women with high and low levels of internalized racism. J Natl Med Assoc 97: 206-212.
103. Ujike H, Takaki M, Nakata K, Tanaka Y, Takeda T, Kodama M et al (2002). CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry 7: 515-518.
104. van der Vegt EJ, van der Ende J, Kirschbaum C, Verhulst FC, Tiemeier H (2009). Early neglect and abuse predict diurnal cortisol patterns in adults A study of international adoptees. Psychoneuroendocrinology 34: 660-669.
105. van Os J, Hanssen M, Bijl RV, Vollebergh W (2001). Prevalence of psychotic disorder and community level of psychotic symptoms: An urban-rural comparison. Arch Gen Psychiatry 58: 663-668.
106. van Os J, Pedersen CB, Mortensen PB (2004). Confirmation of synergy between urbanicity and familial liability in the causation of psychosis. Am J Psychiatry 161: 2312-2314.
107. Walder DJ, Walker EF, Lewine RJ (2000). Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia. Biol Psychiatry 48: 1121-1132.
108. Walker EF, Diforio D (1997). Schizophrenia: A neural diathesisstress model. Psychol Rev 104: 667-685.
109. Walker EF, Trotman HD, Pearce BD, Addington J, Cadenhead KS, Cornblatt BA et al (2013). Cortisol levels and risk for psychosis: Initial findings from the North American prodrome longitudinal study. Biol Psychiatry 74: 410-417.
110. Wang J, Ueda N (2009). Biology of endocannabinoid synthesis system. Prostaglandins Other Lipid Mediat 89: 112-119.
111. Webster MJ, Knable MB, O'Grady J, Orthmann J, Weickert CS (2002). Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Mol Psychiatry 7: 985-994 924.
112. Wong DF, Kuwabara H, Horti AG, Raymont V, Brasic J, Guevara M et al (2010). Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. Neuroimage 52: 1505-1513.
113. Wright IC, Rabe-Hesketh S, Woodruff PW, David AS, Murray RM, Bullmore ET (2000). Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry 157: 16-25.
114. Yamakawa K, Matsunaga M, Isowa T, Kimura K, Kasugai K, Yoneda M et al (2009). Transient responses of inflammatory cytokines in acute stress. Biol Psychol 82: 25-32.
115. Zavitsanou K, Garrick T, Huang XF (2004). Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28: 355-360.